Related Experiment Video
Updated: Jun 25, 2026
09:37
Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure
Published on: December 2, 2014
[Myocardial infarction, left ventricle remodeling and cellular therapy]
H Skalická1, J Horák, M Aschermann
1II. Interní klinika kardiologie a angiologie 1. Lékarské fakulty UK a VFN Praha. skaldah@seznam.cz
Vnitrni Lekarstvi
|February 21, 2009
Summary
Bone marrow stem cell implantation shows promise for treating acute myocardial infarction. This therapy aims to prevent heart failure by regenerating damaged heart tissue.
Area of Science:
- Regenerative Medicine
- Cardiovascular Research
- Hematology
Context:
- Acute myocardial infarction (AMI) leads to significant heart damage and heart failure.
- Current treatments for AMI have limitations, especially for patients with poor long-term prognosis.
- Left ventricular remodeling is a key factor in post-MI heart failure progression.
Purpose:
- To review significant clinical studies on bone marrow stem cell (BMSC) implantation for AMI.
- To evaluate the potential of BMSCs in preventing adverse cardiac remodeling and improving outcomes.
- To highlight the therapeutic possibilities for patients with severe prognoses.
Summary:
- Clinical studies investigate BMSC implantation for acute myocardial infarction.
- The goal is to substitute necrotic/fibrotic tissue and prevent left ventricular remodeling.
- This approach offers hope for patients with poor long-term prognoses despite medical advances.
Impact:
- Potential to halt or reverse heart failure progression after myocardial infarction.
- Offers a novel therapeutic strategy for severe cardiovascular disease.
- May improve long-term survival and quality of life for AMI patients.
More Related Videos
09:11Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
Published on: September 22, 2014
08:24Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
Published on: May 25, 2020
Related Concept Videos
01:21Myocarditis I: Introduction
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...